Optibiotix Health has successfully raised US$1.3 million though a placing of new shares
Optibiotix Health Plc has completed a fundraising to continue the commercialization of its products with corporate and large retail partners, with a particular focus on the company’s SweetBiotix©.
OptiBiotix Health is a life sciences company operating in one of the most progressive areas of biotechnological research. Developing technologies that modulate the human microbiome – the collective genome of the microbes in the body – OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. With an established pipeline of microbiome modulators, the OptiBiotix team is working in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles and diabetes.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Optibiotix Health on its equity fundraising.
Talk to the deal team
PartnerLondon, United Kingdom
Dutch Star Companies TWO succesfully lists in a US$130 million IPO
Dutch Star Companies TWO (DSC2), powered by Oaklins Netherlands, has raised US$130 million and has successfully listed on Euronext Amsterdam with the aim of forming a business combination with a Dutch mid-sized target company.Learn more
Spring has completed an equity raise
The owners and management of Spring have completed a fundraising to support its growth strategy.Learn more
CML Group (ASX:CGR) has completed a placement
CML Group (ASX:CGR) has completed a US$2.5 million placement. The raise was completed at an issue price of US$0.238 (A$0.328) per share to institutional and professional investors. Funds raised will be used to support the company’s cash position to fund growth in its loan book.Learn more